Weight Management

Compounded GLP-1s: What the 2026 FDA Changes Mean for You

What the FDA's 2026 proposal on compounded semaglutide and tirzepatide actually says, why it matters, and what it means if you're considering treatment.

Published August 30, 2026

Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Compounded medications are prepared for individual patients based on a licensed provider's prescription.

Regulatory changes affect which compounded GLP-1 medications can be offered and how. This article explains what the FDA's 2026 proposal says and what it means for patients. For how our program works today, see our medical weight loss program; a licensed provider decides whether any medication is appropriate for you.

What's Changing

Compounding of a drug is only legally permitted under federal law while that drug is on the FDA's official shortage list. Tirzepatide came off that list in December 2024, and semaglutide followed in February 2025.^[1] On April 30, 2026, the FDA went further, proposing to permanently exclude semaglutide, tirzepatide, and liraglutide from the separate list that allows large-scale 503B outsourcing facilities to compound them at all, even outside a shortage.^[2] The public comment period on that proposal closed in late June 2026. As of this writing, the FDA has not issued a final decision — this is a live regulatory process, not a settled outcome.

Why the FDA Is Concerned

The FDA's push isn't just bureaucratic — it's tied to real documented safety issues with some compounded versions: unapproved formulation changes (like semaglutide sodium salt forms, or combining tirzepatide with other ingredients to create a product that isn't the same molecule as the FDA-approved drug), dosing errors from multidose vials requiring self-measurement, and the fact that GLP-1s are fragile peptides vulnerable to improper handling.^[3] These are the FDA's stated reasons for wanting to narrow who can compound these medications and how.

What This Means If You're Considering Treatment

Compounded semaglutide and tirzepatide remain legally available right now through licensed 503A pharmacies. That could change depending on how this proposal is finalized. This is exactly why an evaluation with a licensed provider — not just a signup form — matters: your provider can tell you the current legal and clinical status of any medication at the time you're actually being treated, not based on outdated information.

How Prolong Health Approaches This

Every prescription is reviewed by a licensed provider following a real medical evaluation, and compounded medications are only prescribed when clinically appropriate — never automatically. We've been upfront from the start that compounded medications aren't FDA-approved in the same way brand-name drugs are; this regulatory shift is a reason to stay current on that distinction, not a reason to obscure it.

Getting Started

Complete an intake, get reviewed by a licensed provider, and get accurate, current information about your options.

Start Your Weight Loss Evaluation